PureTech Health plc (NASDAQ:PRTC - Get Free Report)'s share price gapped down before the market opened on Tuesday . The stock had previously closed at $20.50, but opened at $19.24. PureTech Health shares last traded at $21.20, with a volume of 8,433 shares changing hands.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the company. Leerink Partnrs upgraded PureTech Health to a "strong-buy" rating in a report on Monday, September 9th. Leerink Partners began coverage on shares of PureTech Health in a research note on Monday, September 9th. They set an "outperform" rating and a $45.00 price target on the stock.
Check Out Our Latest Stock Report on PureTech Health
PureTech Health Trading Up 3.4 %
The company has a fifty day simple moving average of $20.92 and a two-hundred day simple moving average of $24.30.
Institutional Investors Weigh In On PureTech Health
An institutional investor recently bought a new position in PureTech Health stock. AWM Investment Company Inc. acquired a new position in PureTech Health plc (NASDAQ:PRTC - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,900 shares of the company's stock, valued at approximately $197,000. 0.04% of the stock is owned by hedge funds and other institutional investors.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Further Reading
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
